2023 Western Australian Vaccine Safety Surveillance (WAVSS) Report

Since its establishment in 2011, WAVSS has monitored vaccine safety for Western Australia.

The below data summarises findings from 2023

Adverse Events Following Immunisation (AEFI)

An unwanted or unexpected event following the administration of a vaccine(s) which could be mild, such as a sore arm, or serious, such as anaphylaxis





O 1 0/0
of reports were reviewed as not serious

Most reactions were minor, expected (e.g. tiredness, injection site reaction,


headache) and resolved quickly

WAVSS monitored events of special interest


- Anaphylaxis
- Immune thrombocytopenic purpura
- Febrile convulsions
- Guillain-Barre syndrome
- Myocarditis

- Myopericarditis
- Pericarditis
- Menstrual disturbance
- Thrombosis with thrombocytopenia syndrome

Reports by age group



No safety issues were detected, and results were consistent with those expected from clinical trials



Types of surveillance WAVSS uses



Passive reports from providers and public



